From CGM and smart insulin pens to needle‐free injection technologies and HCL systems, these innovations not only reduce the risk of hypoglycemia and improve insulin therapy precision but also facilitate the transition from patient‐dependent management to data‐driven, automated adjustments, offering more individualized solutions for elderly diabetic patients. This evidence concerns the gene INS and Hypoglycemia.